Quarterly report pursuant to Section 13 or 15(d)

Excess Lease Liability

Excess Lease Liability
6 Months Ended
Jun. 30, 2012
Excess Lease Liability [Abstract]  

On August 21, 2008, Sonus Pharmaceuticals, Inc. (“Sonus”) completed a transaction (“the Arrangement”) with OncoGenex Technologies Inc., (“OncoGenex Technologies”) whereby Sonus acquired all of the outstanding preferred shares, common shares and convertible debentures of OncoGenex Technologies. Sonus then changed its name to OncoGenex Pharmaceuticals, Inc. Prior to the Arrangement, Sonus entered into a non-cancellable lease arrangement for office space located in Bothell, Washington, which is considered to be in excess of the Company’s current requirements. The Company is currently in the process of evaluating opportunities to exit or sublet portions of the leased space. The estimated value of the liability remaining with respect to excess facilities was $7.0 million as of December 31, 2011. In the six months ended June 30, 2012, with respect to excess facilities, $0.3 million was amortized into income resulting in a remaining liability of $6.7 million at June 30, 2012. The liability is computed as the present value of the difference between the remaining lease payments due less the estimate of net sublease income and expenses and has been accounted for in accordance with the then effective EITF No. 95-3, “Recognition of Liabilities in Connection with a Purchase Business Combination.” This represents the Company’s best estimate of the liability. Subsequent changes in the liability due to changes in estimates of sublease assumptions are recognized as adjustments to excess lease charges in future periods.


    Remaining     Amortization     Additional     Remaining  
    Liability at     of excess     Liability     Liability  
(In thousands)   December 31, 2011     lease facility     Recorded     at June 30, 2012  

Current portion of excess lease facility

    1,388       (20     —         1,408  

Long-term portion of excess lease facility

    5,651       408       —         5,243  














    7,039       388       —         6,651